How India Exports Ibuprofen-paracetamol to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for fixed-dose combinations of ibuprofen and paracetamol (acetaminophen). This indicates that no generic versions of this combination have received FDA approval for marketing in the United States. Consequently, Indian exporters aiming to introduce ibuprofen-paracetamol combinations into the U.S. market must navigate the New Drug Application (NDA) or ANDA pathways, ensuring compliance with FDA regulations, including demonstrating bioequivalence and adherence to current Good Manufacturing Practices (cGMP).

Given the absence of approved ANDAs for this combination, there are no specific import alerts related to ibuprofen-paracetamol products. However, the FDA maintains stringent oversight on imported pharmaceuticals. Indian exporters must ensure that their manufacturing facilities are registered with the FDA and that their products meet all regulatory requirements to avoid potential import detentions or refusals. The presence of 58 active Indian exporters and 75 buyers, with a repeat buyer rate of 44.0%, underscores the importance of maintaining high regulatory standards to sustain and expand market presence.

In the European Union, the European Medicines Agency (EMA) has evaluated fixed-dose combinations of paracetamol and ibuprofen. Notably, in May 2017, the EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Paracetamol/Ibuprofen 500 mg/150 mg film-coated tablets outweigh the risks, leading to marketing authorisation in multiple EU Member States, including the United Kingdom. (ema.europa.eu)

Manufacturers exporting to the EU and UK must comply with the Good Manufacturing Practice (GMP) guidelines set forth by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These guidelines ensure that medicinal products are consistently produced and controlled to the quality standards appropriate for their intended use. Compliance with these standards is crucial for market access and maintaining product integrity.

The World Health Organization (WHO) includes both ibuprofen and paracetamol in its Model List of Essential Medicines, recognizing their importance in healthcare systems worldwide. While the WHO Model List does not specifically list the fixed-dose combination of ibuprofen and paracetamol, the individual components' inclusion underscores their therapeutic significance.

Manufacturers should ensure that their products meet the standards set by recognized pharmacopoeias, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is essential for product quality and acceptance in international markets.

In India, the Central Drugs Standard Control Organisation (CDSCO) classifies fixed-dose combinations of ibuprofen and paracetamol under Schedule H, indicating that they are prescription-only medicines. Manufacturers and exporters must comply with the Drugs and Cosmetics Act and Rules, ensuring that products meet the required quality standards and are accompanied by appropriate documentation.

The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines in India. While specific ceiling prices for ibuprofen-paracetamol combinations may vary, manufacturers should stay informed about any pricing notifications to ensure compliance. Additionally, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is a prerequisite for exporting pharmaceutical products, ensuring that all regulatory requirements are met.

As of March 2026, there are no active patents or exclusivity rights associated with the fixed-dose combination of ibuprofen and paracetamol. This absence of patent protection allows for the production and export of generic versions of this combination, facilitating competition and potentially leading to more affordable options for consumers in various markets.

In February 2026, the UK's MHRA issued a Class 3 medicines recall for specific batches of ibuprofen 200 mg tablets due to findings of foil perforations in some blisters. This precautionary measure underscores the importance of stringent quality control in pharmaceutical manufacturing. (gov.uk)

In May 2024, the EMA recommended the refusal of authorisation for Ibuprofen NVT 400 mg soft capsules, concluding that the benefits did not outweigh the risks. This decision highlights the critical role of demonstrating bioequivalence and safety in the approval process for generic medicines. (ema.europa.eu)

In February 2024, the EMA granted marketing authorisation for Ibuprofen Gen.Orph, a generic version of ibuprofen, indicating continued opportunities for generic medicines in the European market. (ema.europa.eu)

In July 2020, the EMA recommended the authorisation of Ibuprofen Kabi 400 mg solution for infusion, reflecting the agency's support for diverse formulations of ibuprofen to meet varying patient needs. (ema.europa.eu)

In May 2017, the EMA's CHMP concluded that the benefits of Paracetamol/Ibuprofen 500 mg/150 mg film-coated tablets outweigh the risks, leading to marketing authorisation in multiple EU Member States, including the United Kingdom. (ema.europa.eu)

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of staying informed about regulatory decisions and quality standards to ensure successful market access and compliance.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) synthesis. Approximately 70–80% of KSMs are imported from China, making India vulnerable to supply chain disruptions. This dependency is particularly critical for drugs like ibuprofen and paracetamol, where China controls a significant portion of the global supply.

Recent geopolitical tensions have exacerbated these vulnerabilities. In February 2026, the closure of the Strait of Hormuz disrupted the supply of petrochemical feedstocks, impacting API production in Asia. Such events underscore the risks associated with over-reliance on a single country for critical raw materials.

Our data indicates that the top five exporters of ibuprofen-paracetamol from India account for 74.1% of the total export value, with BASE PHARMACY INDIA alone contributing 45.3%. This high supplier concentration poses a significant risk; any disruption affecting these key players could severely impact global supply chains.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API manufacturing and reduce dependence on imports. By November 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and Clavulanic Acid, marking a step towards self-reliance.

The closure of the Strait of Hormuz in February 2026 has had profound implications for global supply chains. Approximately 20% of the world's oil transits through this chokepoint, and its disruption has led to increased energy costs and logistical challenges. Pharmaceutical supply chains, particularly those reliant on temperature-controlled transport and time-sensitive inputs, are vulnerable to such disruptions.

Additionally, tensions in the Red Sea and the Suez Canal have further complicated shipping routes, leading to delays and increased costs. These geopolitical events highlight the fragility of global supply chains and the need for diversified sourcing strategies.

• Diversify Supplier Base: Engage with a broader range of suppliers to reduce dependency on a few key players, thereby mitigating risks associated with supplier concentration.

• Enhance Domestic Production: Invest in domestic API and KSM manufacturing capabilities to reduce reliance on imports, leveraging government initiatives like the PLI scheme.

• Develop Alternative Shipping Routes: Establish and utilize alternative shipping routes to circumvent geopolitical hotspots, ensuring continuity in supply chains.

• Strengthen Inventory Management: Maintain strategic stockpiles of critical raw materials and finished products to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Implement robust monitoring systems to stay informed about geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH